Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 647 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Torisel Clear all
Not listed Phase 4 Interventional

Use of Sirolimus vs. Tacrolimus For African-American Renal Transplant Recipients

NCT00252655
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Rapamune and Prograf
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

NCT01353625
View directory record Official record
Conditions
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma, Chronic Lymphocytic Leukemia, Neoplasm Metastasis
Interventions
CC-115
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias

NCT00780104
View directory record Official record
Conditions
Myeloid Leukemias, AML, Leukemia, CML
Interventions
Rapamycin, Mitoxantrone, Etoposide, Cytarabine, Rapamycin + MEC
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 2 Interventional Results available

Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery

NCT01229943
View directory record Official record
Conditions
Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Pancreatic Vipoma
Interventions
Bevacizumab, Everolimus, Octreotide Acetate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
388
States / cities
Mobile, Alabama • Anaheim, California • Antioch, California + 272 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional

Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

NCT01122615
View directory record Official record
Conditions
Renal Cell Cancer, Kidney Cancer
Interventions
Sunitinib, Temsirolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional Results available

Study of Everolimus (RAD001) in Combination With Lenalidomide

NCT01218555
View directory record Official record
Conditions
Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors
Interventions
Lenalidomide, Everolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 31, 2026, 12:14 PM EDT
Terminated Phase 2 Interventional

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

NCT03942601
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Temsirolimus, Temsirolimus and dexamethasone sodium phosphate
Drug
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 2 Interventional Results available

Open-Label of SPN-820 in Adults With Major Depressive Disorder

NCT06235905
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NV-5138
Drug
Lead sponsor
Navitor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Temecula, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 2 Interventional Results available

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

NCT02091531
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
MLN0128
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

NCT01473095
View directory record Official record
Conditions
Solid Tumor, Malignant Lymphoma, Tumor
Interventions
ARQ 092
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 31, 2026, 12:14 PM EDT
Recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

NCT04469530
View directory record Official record
Conditions
Solid Tumor
Interventions
Sirolimus, Cyclophosphamide, Etoposide, Celecoxib
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 12:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

NCT02987959
View directory record Official record
Conditions
Soft-tissue Sarcoma
Interventions
TAK-228
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional Results available

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

NCT01920061
View directory record Official record
Conditions
Neoplasm
Interventions
PF-05212384 (gedatolisib), Docetaxel, Cisplatin, Dacomitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 2 Interventional Results available

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00376688
View directory record Official record
Conditions
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Temsirolimus
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

NCT01163357
View directory record Official record
Conditions
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Other · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional

CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors

NCT00098501
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pelitinib, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 31, 2026, 12:14 PM EDT
Active, not recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

NCT02574728
View directory record Official record
Conditions
Cancer
Interventions
Sirolimus, Celecoxib, Etoposide, Cyclophosphamide
Drug
Lead sponsor
Emory University
Other
Eligibility
12 Months to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00935792
View directory record Official record
Conditions
Lymphocytic Leukemia
Interventions
alemtuzumab, everolimus
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 31, 2026, 12:14 PM EDT
Terminated Not applicable Interventional Results available

A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

NCT01369433
View directory record Official record
Conditions
Solid Tumors
Interventions
Tivozanib + paclitaxel, Tivozanib + temsirolimus, Tivozanib, Tivozanib (AV-951), Tivozanib + capecitabine, Tivo
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
27
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 31, 2026, 12:14 PM EDT
Terminated Phase 3 Interventional

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

NCT00083993
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
112
States / cities
Hoover, Alabama • Huntsville, Alabama • Tucson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 2 Interventional Results available

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

NCT02959918
View directory record Official record
Conditions
Gout Chronic, Hyperuricemia
Interventions
SEL-212, SEL-037, SVP-rapamycin (SEL-110)
Drug
Lead sponsor
Selecta Biosciences, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Anaheim, California • El Cajon, California • Irvine, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 31, 2026, 12:14 PM EDT
Recruiting No phase listed Observational

Safety and Durability of Sirolimus for Treatment of LAM

NCT02432560
View directory record Official record
Conditions
Lymphangioleiomyomatosis
Interventions
Sirolimus, Everolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
20
States / cities
Stanford, California • Denver, Colorado • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 31, 2026, 12:14 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

NCT01522820
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative, Estrogen Receptor Positive, Glioblastoma, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Metastatic Renal Cell Cancer, Recurrent Adult Brain Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Lung Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Uterine Corpus Carcinoma, Resectable Hepatocellular Carcinoma, Sarcoma, Stage IA Breast Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Lung Carcinoma, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Esophageal Cancer, Stage IIB Lung Carcinoma, Stage IIB Ovarian Cancer, Stage IIB Skin Melanoma, Stage IIC Ovarian Cancer, Stage IIC Skin Melanoma, Stage IIIA Breast Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Lung Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIA Skin Melanoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Skin Melanoma, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Skin Melanoma, Stage IIIC Uterine Corpus Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Esophageal Cancer, Stage IV Ovarian Cancer, Stage IV Prostate Cancer, Stage IV Skin Melanoma, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study, Sirolimus
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 31, 2026, 12:14 PM EDT
Active, not recruiting Phase 1 Interventional

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT01375829
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Ixabepilone, Pharmacological Study, Temsirolimus
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 12:14 PM EDT